PE20091041A1 - Producto de dispersion solida que contiene un compuesto a base de n-aril urea - Google Patents

Producto de dispersion solida que contiene un compuesto a base de n-aril urea

Info

Publication number
PE20091041A1
PE20091041A1 PE2008001785A PE2008001785A PE20091041A1 PE 20091041 A1 PE20091041 A1 PE 20091041A1 PE 2008001785 A PE2008001785 A PE 2008001785A PE 2008001785 A PE2008001785 A PE 2008001785A PE 20091041 A1 PE20091041 A1 PE 20091041A1
Authority
PE
Peru
Prior art keywords
acceptable
solid dispersion
alcoxy
union
absent
Prior art date
Application number
PE2008001785A
Other languages
English (en)
Inventor
Rudolf Schroeder
Tanja Heitermann
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of PE20091041A1 publication Critical patent/PE20091041A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

REFERIDA A UNA DISPERSION SOLIDA QUE COMPRENDE: A) UN GENTE ACTIVO DE FORMULA I, DONDE X1 ES N, CR1; X2 ES N, CR2; X3 ES N, CR3, CR3; X4 ES UNION, N, CR4; X5 ES N, C; Z1 ES O, NH, S; Z2 ES UNION, NH, O; Ar1 ES INDAZOL, ISOQUINOLIN SUSTITUIDO; R1, R3, R5, R6 Y R7 SON CADA UNO H, ALCOXI, ALQUILO, ALQUILTIO, ENTRE OTROS; R2 Y R4 SON CADA UNO H, ALQUENILO, ALCOXI, ALQUILCARBONILO, ENTRE OTROS; R8a ESTA AUSENTE O ES H, ALQUILO; R8b ESTA AUSENTE O ES H, ALCOXI, HALOGENO, ENTRE OTROS ; B) AGENTE FORMADOR DE MATRIZ ACEPTABLE PARA USO FARMACEUTICO SELECCIONADO ENTRE POLI N-VINILPIRROLIDONAS, ACETATO DE VINILO, COPOLIMEROS DE N-VINIL PIRROLIDONA Y COMBINACIONES DE LOS MISMOS; C) UNA COMBINACION DE 2 O MAS TENSIOACTIVOS ACEPTABLES PARA USO FARMACEUTICO DE PREFERENCIA SUCCINATO DE ALFA-TOCOFERIL POLIETILENGLICOL Y GLICERIDO POLALCOXILADO D) AL MENOS UN SOLVENTE. LA RELACION DE MASA ENTRE EL AGENTE ACTIVO Y AGENTE FORMADOR DE MATRIZ ES 0,1:1 Y 1:3. UN AGENTE ACTIVO PREFERIDO ES: N-(5-TERT-BUTIL-2,3-DIHIDRO-1H-INDEN-1-IL)-N'-5-ISOQUINOLINILUREA. DICHO PRODUCTO DE DISPERSION PERMITE UNA FORMULACION SOLIDA DE AGENTE ACTIVOS DE BAJA SOLUBILIDAD CON CONCENTRACION ALTA DE DROGA Y BIODISPONIBILIDAD ACEPTABLE
PE2008001785A 2007-10-19 2008-10-17 Producto de dispersion solida que contiene un compuesto a base de n-aril urea PE20091041A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961307P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
PE20091041A1 true PE20091041A1 (es) 2009-08-22

Family

ID=40089072

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001785A PE20091041A1 (es) 2007-10-19 2008-10-17 Producto de dispersion solida que contiene un compuesto a base de n-aril urea

Country Status (23)

Country Link
US (1) US20090143423A1 (es)
EP (1) EP2197426A2 (es)
JP (1) JP2011500647A (es)
KR (1) KR20100090689A (es)
CN (1) CN101827585A (es)
AR (1) AR068916A1 (es)
AU (1) AU2008313620A1 (es)
BR (1) BRPI0818339A2 (es)
CA (1) CA2699335A1 (es)
CL (1) CL2008003092A1 (es)
CO (1) CO6270303A2 (es)
CR (1) CR11441A (es)
DO (1) DOP2010000114A (es)
EC (1) ECSP10010184A (es)
GT (1) GT201000095A (es)
MX (1) MX2010004292A (es)
PE (1) PE20091041A1 (es)
RU (1) RU2010119924A (es)
TW (1) TW200922549A (es)
UA (1) UA100866C2 (es)
UY (1) UY31406A1 (es)
WO (1) WO2009050289A2 (es)
ZA (1) ZA201002130B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045402A1 (en) * 2008-10-17 2010-04-22 Abbott Laboratories Trpv1 antagonists
AR073631A1 (es) * 2008-10-17 2010-11-17 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
WO2011032860A1 (de) * 2009-09-18 2011-03-24 Basf Se Verfahren zur herstellung von zubereitungen von in wasser schwerlöslichen substanzen
EP2654731B1 (en) * 2010-12-23 2016-07-27 AbbVie Deutschland GmbH & Co. KG Solid retard formulations based on solid dispersions
CN103391770A (zh) 2011-01-10 2013-11-13 细胞基因公司 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
EP2907505A3 (en) * 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
EA032322B1 (ru) 2013-03-15 2019-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Твердая пероральная дозированная композиция ингибитора hcv в аморфном состоянии
US10046151B2 (en) 2013-07-03 2018-08-14 Lts Lohmann Therapie-Systeme, Ag Transdermal therapeutic system with electronic component
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
CN106456566B (zh) * 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
CA3039767C (en) * 2015-12-22 2023-11-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
CA3117563A1 (en) * 2018-10-30 2020-05-07 Peloton Therapeutics, Inc. Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
JP6830569B1 (ja) 2019-08-23 2021-02-17 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
EP0642498A1 (en) * 1992-05-28 1995-03-15 Pfizer Inc. NEW $i(N)-ARYL AND $i(N)-HETEROARYLUREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A:CHOLESTEROL ACYL TRANSFERASE (ACAT)
CA2302735A1 (en) * 1998-07-14 2000-01-27 Em Industries, Inc. Microdisperse drug delivery systems
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
BRPI0511900A (pt) * 2004-06-08 2008-01-22 Vertex Pharma composições farmacêuticas
JP5128948B2 (ja) * 2004-08-27 2013-01-23 ニッポネックス インコーポレイテッド 癌の治療のための新規な薬剤組成物
MX2007012947A (es) * 2005-04-18 2008-04-09 Rubicon Res Pvt Ltd Composiciones biomejoradas.
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
US7745448B2 (en) * 2005-12-28 2010-06-29 Abbott Laboratories Inc. Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate
JP5773560B2 (ja) * 2006-02-09 2015-09-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｅｔｐ阻害剤のポリマー製剤

Also Published As

Publication number Publication date
UY31406A1 (es) 2009-05-29
CL2008003092A1 (es) 2009-11-27
JP2011500647A (ja) 2011-01-06
CN101827585A (zh) 2010-09-08
RU2010119924A (ru) 2011-11-27
BRPI0818339A2 (pt) 2015-04-22
ZA201002130B (en) 2011-11-30
DOP2010000114A (es) 2010-05-15
CR11441A (es) 2010-10-25
CO6270303A2 (es) 2011-04-20
ECSP10010184A (es) 2010-06-29
GT201000095A (es) 2012-04-03
KR20100090689A (ko) 2010-08-16
UA100866C2 (ru) 2013-02-11
MX2010004292A (es) 2010-08-02
CA2699335A1 (en) 2009-04-23
AR068916A1 (es) 2009-12-16
TW200922549A (en) 2009-06-01
WO2009050289A3 (en) 2010-03-25
WO2009050289A2 (en) 2009-04-23
US20090143423A1 (en) 2009-06-04
AU2008313620A1 (en) 2009-04-23
EP2197426A2 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
PE20091041A1 (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
AR027548A1 (es) Derivados de amino pirazol utiles para el tratamiento de la obesidad y otros desordenes
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
PE20010286A1 (es) Derivados de indoloxoacetil piperazina como agentes antivirales
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
ECSP045519A (es) Nuevos derivados de quinuclidina-amida
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
UY29609A1 (es) Derivados de benzamidina y usos relacionados de los mismos
AR045039A1 (es) Dispositivo de administracion de drogas oftalmicas
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
AR051315A1 (es) Pirimidinas 5-sustituidas inhibidoras del vih
SG164283A1 (en) New benzimidazole derivatives
UY28510A1 (es) Compuestos quimicos
CL2007001090A1 (es) Compuestos derivados de diazepano, antagonistas de los receptores ccr-2, ccr-5 y ccr-3; procedimiento de preparacion; composicion farmaceutica; compuesto intermediario; y uso del compuesto en el tratamiento de una enfermedad oclusiva de arterias perifericas, isquemia critica de extremidades, angina inestable, apoplejia, entre otras
AR061918A1 (es) Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
PA8623101A1 (es) Compuestos farmaceuticamente activos
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
AR047466A1 (es) Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles.
CO5560559A2 (es) Formulacion de suspension oral estabilizada
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
AR013503A1 (es) Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed